Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas

APMIS

Volumn 118, Issue 10, 2010, Pages 769-776

  SÖderstrÖm, Mirva ^a   Palokangas, Tuire ^b   Vahlberg, Tero ^b   BÖhling, Tom ^c   Aro, Hannu ^a   Carpen, Olli ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Bcl 2; Chondrosarcoma; ezrin; Ki 67

Indexed keywords

EZRIN; KI 67 ANTIGEN; PROTEIN BCL 2; TUMOR MARKER; CYTOSKELETON PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CHONDROSARCOMA; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TUMOR GROWTH; ADOLESCENT; BIOSYNTHESIS; BONE TUMOR; IMMUNOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; TISSUE MICROARRAY; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHONDROSARCOMA; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-BCL-2; STATISTICS, NONPARAMETRIC; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 77956896015     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02656.x     Document Type: Article

References (33)

1. Chow WA. Update on chondrosarcomas. Curr Opin Oncol 2007 19 : 371 6.
2. Vaheri A, Carpen O, Heiska L, Helander TS, Jaaskelainen J, Majander-Nordenswan P, et al. The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol 1997 9 : 659 66.
3. Mackay DJ, Esch F, Furthmayr H, Hall A. Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrinradixinmoesin proteins. J Cell Biol 1997 138 : 927 38.
4. Dransfield DT, Bradford AJ, Smith J, Martin M, Roy C, Mangeat PH, et al. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J 1997 16 : 35 43.
5. Gautreau A, Poullet P, Louvard D, Arpin M. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinaseAkt pathway. Proc Natl Acad Sci USA 1999 96 : 7300 5.
6. Gautreau A, Louvard D, Arpin M. ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 2002 14 : 104 9.
7. Krieg J, Hunter T. Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin. J Biol Chem 1992 267 : 19258 65.
8. Jiang WG, Hiscox S, Singhrao SK, Puntis MC, Nakamura T, Mansel RE, et al. Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factorscatter factor. Biochem Biophys Res Commun 1995 217 : 1062 9.
9. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002 3 : 586 99.
10. Heiska L, Carpén O. Src phosphorylates ezrin at tyrosine 477 and induces a phosphospecific association between ezrin and a kelch-repeat protein family member. J Biol Chem 2005 280 : 10244 52.
11. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AH, van Wezel T, et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Cancer Res 2009 69 : 6216 22.
12. Chung UI, Lanske B, Lee K, Li E, Kronenberg H. The parathyroid hormoneparathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc Natl Acad Sci USA 1998 95 : 13030 5.
13. Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005 6 : 599 607.
14. Daugaard S, Christensen LH, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS 2009 117 : 518 25.
15. Rozeman LB, Hameetman L, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, Bovee JV. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol 2005 205 : 476 82.
16. Bovee JV, van den Broek LJ, Cleton-Jansen AM, Hogendoorn PC. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000 80 : 1925 34.
17. Hameetman L, Kok P, Eilers PH, Cleton-Jansen AM, Hogendoorn PC, Bovee JV. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 2005 446 : 430 7.
18. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003 22 : 7414 30.
19. Kim R, Emi M, Tanabe K, Toge T. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 2004 101 : 2491 502.
20. Geiger KD, Stoldt P, Schlote W, Derouiche A. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 2000 157 : 1785 17893.
21. Tynninen O, Carpén O, Jääskeläinen J, Paavonen T, Paetau A. Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol 2004 30 : 472 7.
22. Mäkitie T, Carpén O, Vaheri A, Kivelä T. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci 2001 42 : 2442 9.
23. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O. Ezrin in primary cutaneous melanoma. Mod Pathol 2005 18 : 503 10.
24. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004 10 : 182 6.
25. Bruce B, Khanna G, Ren L, Landberg G, Jirstrom K, Powell C, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007 24 : 69 78.
26. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977 40 : 818 31.
27. Böhling T, Turunen O, Jääskeläinen J, Carpen O, Sainio M, Wahlström T, et al. Ezrin expression in stromal cells of capillary hemangioblastoma. An immunohistochemical survey of brain tumors. Am J Pathol 1996 148 : 367 73.
28. Moilanen J, Lassus H, Leminen A, Vaheri A, Bützow R, Carpén O. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 2003 90 : 273 81.
29. Salas S, de Pinieux G, Gomez-Brouchet A, Larrousserie F, Leroy X, Aubert S, et al. Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma. Virchows Arch 2009 454 : 81 7.
30. Terek RM, Schwartz GK, Devaney K, Glantz L, Mak S, Healey JH, et al. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 1998 16 : 585 90.
31. Kim DW, Kim KO, Shin MJ, Ha JH, Seo SW, Yang J, et al. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer 2009 8 : 28.
32. Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, Weller M. Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci 2001 21 : 3360 8.
33. Wick W, Wild-Bode C, Frank B, Weller M. BCL-2-induced glioma cell invasiveness depends on furin-like proteases. J Neurochem 2004 91 : 1275 83.